Instruction for use: Poludanum

Dosage form: Nasal drops; Lyophilizate for the preparation of eye drops; Lyophilizate for the preparation of nasal drops; Lyophilizate for solution for injection

Active substance: Acidum polyadenilicum+Acidum polyuridilicum

ATX

S01AD Antiviral drugs

Pharmacological group:

Other immunomodulators in combinations

The nosological classification (ICD-10)

J06 Acute upper respiratory tract infections of multiple and unspecified locations: Frequent colds of viral diseases; Infections of ENT organs; Acute respiratory illness of influenza nature; Pain for colds; Acute catarrhal disease; Cold; Colds; Colds; Respiratory infection; Seasonal catarrhal disease; Seasonal colds; Pain in infectious and inflammatory diseases of the upper respiratory tract; Bacterial infections of the upper respiratory tract; Bacterial infections of the respiratory system; Viral respiratory disease; Viral respiratory tract infections; Inflammatory disease of the upper respiratory tract; Inflammatory diseases of the upper respiratory tract; Inflammatory diseases of the upper respiratory tract with difficult to separate sputum; Inflammatory respiratory disease; Secondary infections for colds; Difficult sputum separation in acute and chronic respiratory diseases; Upper respiratory tract infections; Infections of the upper respiratory tract; Respiratory tract infections; Respiratory and lung infections; Infectious-inflammatory diseases of the upper respiratory tract; Infectious-inflammatory diseases of the upper respiratory tract and ENT organs; Infectious-inflammatory diseases of the upper respiratory tract in adults and children; Infectious-inflammatory diseases of the upper respiratory tract; Infectious inflammation of the respiratory tract; Respiratory tract infection; Qatar upper respiratory tract; Catarrh of the upper respiratory tract; Catarrh of the upper respiratory tract; Catarrhal phenomena from the upper respiratory tract; Cough in diseases of the upper respiratory tract; Cough for colds; ARVI; ARI; ARI with phenomena of rhinitis; Acute respiratory infection; Acute infectious-inflammatory disease of the upper respiratory tract; Acute respiratory disease; Persecution in the throat or nose; Respiratory and viral infections; Respiratory diseases; Respiratory infections; Recurrent respiratory tract infections; Secondary infections with influenza; Influenza states; Feverish conditions for influenza

J11 Influenza, virus not identified: Influenza; Influenza in the early stages of the disease; Influenza in children; cold in the chest; Begins flu-like condition; Acute disease parainfluenza; parainfluenza; parainfluenza state; influenza epidemics; The pains of the influenza

Composition and release form

Lyophilizate for the preparation of nasal drops 1 fl.

Polyriboadenyl acid potassium salt (potassium polyriboadenylate) 0.1 mg

Polyribouridic acid potassium salt (potassium polyribourouslidate) 0.107 mg

Auxiliary substances: sodium hydrogen phosphate (sodium dihydrogen phosphate) 2.0 mg; Potassium dihydrogen phosphate (potassium phosphate monohydrate anhydrous) - 0.408 mg; Sodium chloride - 8.5 mg

In bottles of 5 ml volume of 100 units, complete with 1 or 3 sterile dropper caps; In a carton box 1 or 3 sets.

Pharmachologic effect

Mode action - immunomodulating.

Pharmacodynamics

Poludan is a biosynthetic polyribonucleotide complex of polyriboadenyl and polyribouridyl acids. Inductor synthesis of endogenous interferon and other cytokines. Stimulates the formation, mainly alpha-interferon, to a lesser extent - beta and gamma-interferon. It induces the synthesis of interferon in peripheral blood leukocytes, as well as in tissues and organs containing lymphoid elements. A high level of interferon is maintained by daily administration throughout the course. Has a direct antiviral effect against influenza viruses and other acute respiratory viral infections. Modulates the cytokine response when the cells are infected with a virus.

Indications for the preparation Poludanum

Treatment of acute respiratory infections, incl. Influenza.

Contraindications

Hypersensitivity to the components of the drug.

Side effects

Allergic reactions are rare.

Interaction

With the simultaneous use of Poludanum® with enzyme preparations, its clinical efficacy is reduced due to the destructive effect of enzymes on endogenous interferon. Compatible with antibiotics and drugs for the treatment of viral infections.

Dosing and Administration

Locally.

The drug is used in adults to treat influenza and other acute respiratory infections in the form of drops in the nose. Bury 2 drops in each nostril 5 times a day for 5 days in the acute period of the disease - no later than 24-48 hours after the first symptoms appear.

A solution of Poludanum® is prepared by dissolving the contents of the vial (100 units) with boiled water until the label shown on the label.

Special instruction

Adverse events are transient in nature and disappear after drug withdrawal in 1-3 days.

Storage conditions of the drug Poludanum

In a dry, the dark place at a temperature of no higher than 4 ° C.

Keep out of the reach of children.

Shelf life of the drug Poludanum

4 years.

Do not use after the expiry date printed on the package.